©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2024; 16(9): 1245-1257
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1245
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1245
Drainage of ascites in cirrhosis
Jia-Xing Yang, Hao-Tian Zeng, Xi-Min Lin, Department of Gastroenterology, The Second Clinical Medical College, Jinan University, Shenzhen 518000, Guangdong Province, China
Yue-Ming Peng, Department of Nursing, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, Shenzhen 518000, Guangdong Province, China
Zheng-Lei Xu, Department of Gastroenterology, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, Shenzhen 518000, Guangdong Province, China
Co-first authors: Jia-Xing Yang and Yue-Ming Peng.
Author contributions: Yang JX and Peng YM contributed equally to this work; Yang JX, Zeng HT, Lin XM, Xu ZL wrote the manuscript; All authors have read and approved the final manuscript.
Supported by Sanming Project of Medicine in Shenzhen , No. SZSM202211029 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Zheng-Lei Xu, MD, Assistant Professor, Chief Doctor, Department of Gastroenterology, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, No. 1017 Dongmen North Road, Shenzhen 518000, Guangdong Province, China.
Received: July 3, 2024
Revised: July 20, 2024
Accepted: July 29, 2024
Published online: September 27, 2024
Processing time: 82 Days and 7.7 Hours
Revised: July 20, 2024
Accepted: July 29, 2024
Published online: September 27, 2024
Processing time: 82 Days and 7.7 Hours
Core Tip
Core Tip: For cirrhotic refractory ascites, peritoneovenous shunt is rarely used due to its high complication rate. Initial treatment for most refractory ascites prioritizes large-volume paracentesis combined with albumin infusion and peritoneal catheter drainage. If these treatments are ineffective or result in severe complications, transjugular intrahepatic portosystemic shunt or automated low-flow ascites pump may be considered. Cell-free and concentrated ascites reinfusion therapy requires further validation for suitability.